Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma

Despite the availability of new therapies that have led to improved outcomes for patients with multiple myeloma, most patients will eventually relapse. With triplet and even quadruplet combination therapies becoming standard in the first and second line, many patients will have few treatment options...

Descripción completa

Detalles Bibliográficos
Autores principales: Mateos, María-Victoria, Bladé, Joan, Bringhen, Sara, Ocio, Enrique M, Efebera, Yvonne, Pour, Luděk, Gay, Francesca, Sonneveld, Pieter, Gullbo, Joachim, Richardson, Paul G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601491/
https://www.ncbi.nlm.nih.gov/pubmed/32992506
http://dx.doi.org/10.3390/jcm9103120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601491/
https://www.ncbi.nlm.nih.gov/pubmed/32992506
http://dx.doi.org/10.3390/jcm9103120

Ejemplares similares